Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medrx CoTSE:4586 +3.64%57 Forward Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus rates TSE:4586 with a GF Score™ of 57/100 and a GF Value™ of 円70.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 511 Drug Manufacturers companies, Medrx Co ranks worse than 195694.52% on this metric.
As of today (2026-07-15), the Forward Annual Dividend Yield of Medrx Co is 0.00%.
As of today (2026-07-15), the Trailing Annual Dividend Yield of Medrx Co is 0.00%.
TSE:4586's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Medrx Co (TSE:4586) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
TSE:4586 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medrx Co Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medrx Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Medrx Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Medrx Co (TSE:4586) has a Forward Dividend Yield % of 0.00% as of Jul. 15, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Medrx Co and its competitors. According to the industry distribution chart, Medrx Co ranks #999999 out of 511 companies in the Drug Manufacturers industry.
Is Medrx Co's Forward Dividend Yield % too high?
Medrx Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Medrx Co ranks #999999 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medrx Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #999999 out of 511 companies for Forward Dividend Yield %. This places Medrx Co in the lower half of its industry. The industry median Forward Dividend Yield % is 2.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.00, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Medrx Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Modestly Undervalued. The stock's GF Value™ is 円70.55, compared to a current price of 円57.00 — trading 19.2% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Medrx Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current Forward Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medrx Co (TSE:4586) Overvalued in 2026?
Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued.
The current stock price of 円57.00 is trading 19.2% below its estimated GF Value™ of 円70.55.
GuruFocus considers Medrx Co to be Modestly Undervalued.
Key valuation signals for TSE:4586:
Forward Dividend Yield %: 0.00%
GF Value™: 円70.55 vs. price of 円57.00 (19.2% below fair value)
No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
57GF Score
Get the complete analysis for TSE:4586
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4586 has been successfully added to your 
